- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06822426
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult And Adolescent Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Rozšířený přístup
Kontakty a umístění
Studijní kontakt
- Jméno: Liz Hurlburt, Chief Clinical Strategy & Operations Officer
- Telefonní číslo: 908-517-9500
- E-mail: lhurlburt@cormedix.com
Studijní místa
-
-
California
-
Los Angeles, California, Spojené státy, 90024
- Nábor
- University of California Los Angeles
-
Kontakt:
- Michael C Garcia, MD
- Telefonní číslo: 310-206-1987
- E-mail: mcgarcia@mednet.ucla.edu
-
Kontakt:
- Jeraldine Guzman
- Telefonní číslo: 310.206.8292
- E-mail: Jbguzman@mednet.ucla.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- Nábor
- MedStar Health Research Institute
-
Kontakt:
- Jeffrey Shupp, MD
- Telefonní číslo: 202-877-5133
- E-mail: jeffrey.w.shupp@medstar.net
-
Kontakt:
- Alison Ross
- Telefonní číslo: 202-877-5170
- E-mail: fbsrlresearch@medstar.net
-
-
Florida
-
Doral, Florida, Spojené státy, 33122
- Nábor
- Bioresearch Partner
-
Kontakt:
- Rafael Abreu, MD
- Telefonní číslo: 833-489-4968
- E-mail: rabreumd@bioresearchpartner.com
-
Kontakt:
- Keila Hoover
- Telefonní číslo: 833-489-4868
- E-mail: khoovermd@bioresearchpartner.com
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Nábor
- Emory University Hospital - GCRC
-
Kontakt:
- Thomas R Ziegler, MD
- Telefonní číslo: 404-727-7351
- E-mail: tzieg01@emory.edu
-
Kontakt:
- Xu Wang
- E-mail: xwang39@emory.edu
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- Nábor
- University of Chicago Medical Center
-
Kontakt:
- Carol Semrad, MD
- Telefonní číslo: 773-702-6921
- E-mail: csemrad@bsd.uchicago.edu
-
Kontakt:
- Kristi Kearney
- Telefonní číslo: 773-834-7414
- E-mail: kristi.kearney@uchicagomedicine.org
-
Maywood, Illinois, Spojené státy, 60153
- Nábor
- Loyola University Medical Center
-
Kontakt:
- Dejan Micic, MD
- Telefonní číslo: 888-584-7888
- E-mail: dejan.micic@lumc.edu
-
Kontakt:
- Maria Chavez
- Telefonní číslo: 464-220-9498
- E-mail: mchavez11@luc.edu
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- Nábor
- University of Iowa Health Care
-
Kontakt:
- Ethan Hoover, RN, MNHP
- Telefonní číslo: 319-335-9767
- E-mail: ethan-hoover@uiowa.edu
-
Kontakt:
- Divya Ashat, MD
- Telefonní číslo: 319-384-5492
- E-mail: divya-ashat@uiowa.edu
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21205
- Nábor
- Johns Hopkins Clinical Research Unit
-
Kontakt:
- Sara Keller, MD, MPH, MSHP
- Telefonní číslo: 410-952-7572
- E-mail: Skeller9@jhmi.edu
-
Kontakt:
- Marwa El-Ashry, BS
- Telefonní číslo: 667-306-9370
- E-mail: melashr1@jh.edu
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy, 55905
- Nábor
- Mayo Clinic
-
Kontakt:
- Bradley Salonen, MD
- Telefonní číslo: 507-284-4805
- E-mail: Salonen.Bradley@mayo.edu
-
Kontakt:
- Pearl Buabeng
- E-mail: Buabeng.Pearl@mayo.edu
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68198-3285
- Nábor
- University of Nebraska Medical Center
-
Kontakt:
- David F Mercer, MD, PhD, FRCS(C)
- Telefonní číslo: 402-559-6955
- E-mail: dmercer@unmc.edu
-
Kontakt:
- Rachel Harper, RN, BSN
- Telefonní číslo: 402-559-1282
- E-mail: raharper@unmc.edu
-
-
New York
-
New York, New York, Spojené státy, 10032
- Nábor
- Columbia University Irving Medical Center
-
Kontakt:
- Michael Owen-Michaane, MD
- Telefonní číslo: 212-342-3881
- E-mail: mco2125@cumc.columbia.edu
-
Kontakt:
- Brett Gray, ANP, MPH
- Telefonní číslo: 212-305-1570
- E-mail: bg2168@cumc.columbia.edu
-
New York, New York, Spojené státy, 10029
- Nábor
- Mount Sinai Medical Center
-
Kontakt:
- Kishore Iyer, MD
- Telefonní číslo: 212-241-2064
- E-mail: kishore.iyer@mountsinai.org
-
Kontakt:
- Brandy Haydel
- Telefonní číslo: 212-241-0255
- E-mail: brandy.haydel@mountsinai.org
-
New York, New York, Spojené státy, 10016
- Zatím nenabíráme
- NYU Grossman School of Medicine
-
Kontakt:
- Jennifer Katz, MD
- Telefonní číslo: 212-263-3643
- E-mail: jennifer.katz@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Staženo
- Duke University Hospital
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44195
- Nábor
- Cleveland Clinic Foundation
-
Kontakt:
- Cynthia Stokes
- E-mail: stokesc2@ccf.org
-
Kontakt:
- Jessica Sosio, DO
- Telefonní číslo: 216-442-2416
- E-mail: sosioj@ccf.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Nábor
- Hospital of the University of Pennsylvania
-
Kontakt:
- Valerianna Amorosa, MD
- Telefonní číslo: 215-873-4998
- E-mail: Valerianna.Amorosa@pennmedicine.upenn.edu
-
Kontakt:
- Kelly Wall
- E-mail: kelly.wall@pennmedicine.upenn.edu
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Nábor
- Rhode Island Hospital
-
Kontakt:
- Benjamin Hall, MD
- Telefonní číslo: 401-444-4296
- E-mail: benjamin_hall@brown.edu
-
Kontakt:
- Marion Winkler, PhD, RD, LDN, CNSC
- Telefonní číslo: 401-444-4276
- E-mail: mwinkler@brownhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37212-1150
- Nábor
- Vanderbilt Center for Human Nutrition
-
Kontakt:
- Dawn Adams, MD
- Telefonní číslo: 615-936-0192
- E-mail: dawn.w.adams@vumc.org
-
Kontakt:
- Sean Durkin, BS
- Telefonní číslo: 615-343-4216
- E-mail: sean.durkin@vumc.org
-
-
Texas
-
Sugarland, Texas, Spojené státy, 77478
- Nábor
- Alchemi - Sugarland
-
Kontakt:
- Olumayowa Aderinto, MD
- Telefonní číslo: 346- 673-1322
- E-mail: o.aderintomd@alchemirc.com
-
Kontakt:
- Kenneth Morgan, MSc
- Telefonní číslo: 832-307-3100
- E-mail: k.morgan@alchemirc.com
-
-
-
-
Ankara
-
Altındağ, Ankara, Turecko (Türkiye), 06230
- Nábor
- Hacettepe University Hospitals
-
Kontakt:
- Prof. Dr. Meltem Gulhan Halil
- Telefonní číslo: (90) 532 786 45 35
- E-mail: meltemhalil@yahoo.com
-
Kontakt:
- Fatma Tamer
- Telefonní číslo: (90) 533 339 18 11
- E-mail: fatmatamer06@gmail.com
-
Yenimahalle, Ankara, Turecko (Türkiye), 06560
- Nábor
- Hacettepe University Hospitals
-
Kontakt:
- Prof. Dr. Melda Türkoğlu
- Telefonní číslo: (90) 532 523 38 10
- E-mail: meldaturkoglu@yahoo.com
-
Kontakt:
- Assoc. Prof. Dr. Kamil Inci
- Telefonní číslo: (90) 544 212 25 45
- E-mail: kamilinci@gmail.com
-
Çankaya, Ankara, Turecko (Türkiye), 06800
- Nábor
- Ankara Bilkent City Hospital
-
Kontakt:
- Prof. Dr. Mutlu Doganay
- Telefonní číslo: (90) 532 295 60 50
- E-mail: drmdoganay@gmail.com
-
Kontakt:
- Dr. Piril Tuncay
- Telefonní číslo: (90) 505 386 90 32
- E-mail: piril_tuncay@hotmail.com
-
Çankaya, Ankara, Turecko (Türkiye), 06230
- Nábor
- Ankara University Ibni Sina Research and Application Hospital
-
Kontakt:
- Prof. Dr. Seher Demirer
- Telefonní číslo: (90) 532 569 27 12
- E-mail: seher.demirer@gmail.com
-
Kontakt:
- Dr. Süleyman Utku Çelik
- Telefonní číslo: (90) 535 339 16 50
- E-mail: s.utkucelik@hotmail.com
-
-
Istanbul
-
Istanbul, Istanbul, Turecko (Türkiye), 34093
- Nábor
- Istanbul University Faculty of Medicine, Capa State Hospital
-
Kontakt:
- Prof. Dr. Bulent Saka
- Telefonní číslo: (90) 532 366 65 41
- E-mail: bulent.saka@istanbul.edu.tr
-
Kontakt:
- Assoc. Prof. Dr. Mustafa Altinkaynak
- Telefonní číslo: (90) 506 658 15 97
- E-mail: mustafa.altinkaynak@istanbul.edu.tr
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
-
Participants who are resident within study site's country.
-
Participants who are male or female, aged ≥12 years at the time of consent.
-
Participants must sign and provide informed consent. For adolescent participants or participants that require a legal representative, written informed consent will be obtained from the study participant's legal guardian or legal representative and the assent from the participant when applicable. All legal guardians and representatives should be fully informed, and participants should be informed to the fullest extent possible about the study using language and terms they are able to understand.
-
Participants who have a tunneled/non-tunneled CVC or peripherally inserted central catheter (PICC) made of silicone or polyurethane, which has been in place for at least 7 days prior to enrollment.
-
Participants who require long-term (>3 Months) TPN based on the investigator assessments.
-
Participants who require TPN for at least 3 days per week, of which 2 days have to be parenteral nutrition (PN).
-
Participants who have a minimum of a 4-hour CLS dwelling time and are willing to lock all lumens at a minimum of every 7 days.
-
Participants who are clinically stable, in the opinion of the investigator, for at least 4 weeks prior to enrollment.
-
Participants who are able and willing to be trained or have a caregiver who is willing and able to be trained on the instillation, aspiration of DefenCath or heparin, and to maintain a daily diary.
Male or female participants:
-
Women of childbearing potential (WOCBP; see Section 4.5.1) must have a negative pregnancy test at screening (i.e., the participant is not pregnant); not be lactating; and use an acceptable method of contraception including but not limited to, abstinence, bilateral tubal ligation, vasectomized partner, a barrier method (diaphragm or condom), Depo-Provera, intrauterine device, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the program until at least 30 days after the last DefenCath CLS instillation. (NOTE: The participant must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study).
-
Male participants who are sexually active with a female partner of childbearing potential must agree to use male condoms with spermicide, even if the male participant has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last DefenCath CLS instillation.
-
Participants who comply with all study procedures and follow-up evaluations.
Exclusion Criteria:
- Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
- Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
- Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
- Any participant with a secondary CVC in addition to the primary TPN line.
- Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator [tPA]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
- Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
- Any participant using any type of antimicrobial-coated or heparin-coated catheter.
- Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.
- Any participant with a congenitally lethal condition or a life expectancy of less than 6 months.
- Any participant with documented history of an atrial thrombus or known hypercoagulable state.
- Any participant with an open, non-healing skin ulcer.
- Any participant who has received an allogeneic hematopoietic stem cell transplant within the last year.
- Any participant with neutropenia with an absolute neutrophil count <500 cells/μL
- Any participant with current requirement for systemic chemotherapy and or immunosuppression and absolute neutrophil count <500 cells/μL that occured in the past 4 weeks.
- Any participant with known allergies or absolute contraindications to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.
- Any participant taking other medication with known systemic drug interaction with citrate, taurolidine or heparin.
- Any participant anticipating receiving an intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive an intestinal transplant >90 days of study entry may remain on the study as long as they continue to receive TPN.
- Any participant who is pregnant or lactating.
- Any participant receiving continuous TPN (infusion over 24 hours).
- Any participant with any medical conditions that render them unable to, or unlikely to complete the study or would interfere with optimal participation in the study or produce significant risk to participant.
- Any participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Řízení
|
Heparin |
|
Experimentální: DefenCath®
|
for central venous catheter installation use |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study
Časové okno: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI, but fail to complete the 12-month follow-up period of the study. |
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of AEs, SAEs, treatment-emergent adverse events (TEAEs)
Časové okno: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Compare the safety profile of DefenCath for use as a Catheter Lock Solution (CLS) in adult and adolescent participants receiving Total Parenteral Nutrition (TPN) through a Central Venous Catheter (CVC) to the control of heparin CLS |
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
|
Incidence of changes in laboratory evaluations, vital signs, or physical exam findings
Časové okno: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Compare the safety profile of DefenCath for use as a CLS in adult and adolescent participants receiving TPN through a CVC to the control of heparin CLS |
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- NUTRI-GUARD
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Sharibg if protocol and ICF, pending FDA approval of this indication
Časový rámec sdílení IPD
Pending FDA Approval
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- ICF
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .